Labcorp Reports Q3 2026 Growth and Raises Full-Year Earnings Guidance
Labcorp Holdings Inc. (LH) delivered strong third-quarter 2026 results, reporting total revenue of $3.81 billion, a 6.9% increase driven by organic volume growth and strategic acquisitions. Adjusted earnings per share rose 14.5% year-over-year to $4.78, supported by margin expansion in both the Diagnostics and Biopharma Laboratory Services segments. Following these results, management raised its full-year 2026 adjusted EPS guidance to a range of $18.30 to $18.70. While the company is expanding through acquisitions like BioReference and Myriad Genetics assets, leadership issued a warning regarding potential Medicare reimbursement cuts under the Protecting Access to Medicare Act (PAMA), which could impact patient access and laboratory viability in 2027.
Topics: eps beat free cash flow guidance raise revenue growth share buyback